Immunogenicity: is the ability of a particular substance, such as an antigen or epitope, to provoke an immune response in the body of a human and other animal. In other words, immunogenicity is the ability to induce a humoral and/or cell-mediated immune responses.
DATE: January 27, 2021 TIME: 9am PST Well-timed interaction of correctly functioning maternal immune cells is essential to facilitate healthy placenta formation, as the uterine immune enviro...
Date: January 21, 2021 Time: 8:00am (PST), 11:00am (EST) Today, critical reagent characterization is a key component in the overall workflow to establish robust ligand binding assays (e.g.,...
Date: November 13, 2020 10:00am PST, 1:00pm EST Coronavirus disease 2019 (COVID-19) is currently a global pandemic, but human immune responses to the virus remain poorly understood....
Individuals of under-represented minority ancestry are at disproportional risk for higher incidence and mortality rates for particular cancers. The unequal burden of cancer in certain racial...
The structure of N-linked glycans can play a critical role in the pharmacology of therapeutic proteins, potentially affecting immunogenicity, pharmacokinetics and pharmacodynamics. This make...
Richard Hughes: New immunogenicity strategies to meet the needs of a developing pandemic Shortly after the COVID-19 pandemic began, the subject of serological testing for anti-viral antibodi...
While viral fusion proteins are highly desirable for subunit vaccine generation, their inherent metastable nature complicates implementation and development. We have harnessed the structural...
Most currently used conventional influenza vaccines are based on 1940s technology. Advances in immunogen design and vaccine delivery emerging over the last decade open novel opportunities fo...
While the frequency of pandemic threats seems to be increasing, we fortunately have new tools and technologies to make vaccines with more precision and speed and that support a more proactiv...
DATE: July 23, 2020 TIME: 10:00 am PDT The SARS-CoV-2 pandemic has taken a toll on many sectors of the medical community. As the pandemic took a grip on the laboratory, the need for diagnost...
DATE: June 30, 2020 TIME: 8:00am PT, 11:00am Understanding the tumor microenvironment (TME) is essential for the development of effective treatments for cancer patients. Traditional multi...
The 2020 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to rage. While PCR-based assays are used for viral diagnosis, high through-put, rapid s...
Background: CDK4/6 inhibitors increase tumor immunogenicity in preclinical models of breast cancer and several trials combining CDK4/6 inhibitors and anti-PD1/PDL1 therapies are underway. Ho...
Whether you are performing killing assays, characterizing the tumor microenvironment, or investigating immunogenicity, primary cells are essential for the discovery of new therapeutics. Conc...
DATE: December 11, 2019 TIME: 7:00am PST, 10:00am EST Rapid growth in the cell and gene therapy industry has generated an urgent need for robust analytics around characterization of both vec...
DATE: December 5, 2019TIME: 9:00am PST, 12:00pm EST Characterization of the spatial distribution and abundance of proteins and mRNAs with morphological context within tissues e...
Tumor mutational burden (TMB) is an emerging biomarker that correlates with response to immunotherapeutic agents, such as checkpoint inhibitors. Recent studies indicate that a high mutation l...
DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
Whether you are performing killing assays, immunophenotyping of TILs, characterizing the tumor microenvironment, or investigating immunogenicity, primary cells are essential for the discovery...
As the pace of biotherapeutic approvals increases, so does the pressure on makers of new biologics to complete their development processes faster and more efficiently. The success of the drug...
DATE: January 25, 2018TIME: 10:00am PST, 1:00pm EST, 6:00pm GMTOncolytic virotherapy, the use of viral vectors to treat cancer, holds huge promise. Viruses are natural DNA delivery vehi...
There has been a great deal of renewed attention in immuno-oncology over the last decade. Therapies for cancer are being developed, approved, and administered that can either initiate,...
DATE: August 31, 2017TIME: 7:00am PT, 10:00am ET, 4:00pm CETA tuberculosis (TB) vaccine consisting of a recombinant fusion protein (referred to as H4) combined with a novel sy...
DATE: January 27, 2021 TIME: 9am PST Well-timed interaction of correctly functioning maternal immune cells is essential to facilitate healthy placenta formation, as the uterine immune enviro...
Date: January 21, 2021 Time: 8:00am (PST), 11:00am (EST) Today, critical reagent characterization is a key component in the overall workflow to establish robust ligand binding assays (e.g.,...
Date: November 13, 2020 10:00am PST, 1:00pm EST Coronavirus disease 2019 (COVID-19) is currently a global pandemic, but human immune responses to the virus remain poorly understood....
Individuals of under-represented minority ancestry are at disproportional risk for higher incidence and mortality rates for particular cancers. The unequal burden of cancer in certain racial...
The structure of N-linked glycans can play a critical role in the pharmacology of therapeutic proteins, potentially affecting immunogenicity, pharmacokinetics and pharmacodynamics. This make...
Richard Hughes: New immunogenicity strategies to meet the needs of a developing pandemic Shortly after the COVID-19 pandemic began, the subject of serological testing for anti-viral antibodi...
While viral fusion proteins are highly desirable for subunit vaccine generation, their inherent metastable nature complicates implementation and development. We have harnessed the structural...
Most currently used conventional influenza vaccines are based on 1940s technology. Advances in immunogen design and vaccine delivery emerging over the last decade open novel opportunities fo...
While the frequency of pandemic threats seems to be increasing, we fortunately have new tools and technologies to make vaccines with more precision and speed and that support a more proactiv...
DATE: July 23, 2020 TIME: 10:00 am PDT The SARS-CoV-2 pandemic has taken a toll on many sectors of the medical community. As the pandemic took a grip on the laboratory, the need for diagnost...
DATE: June 30, 2020 TIME: 8:00am PT, 11:00am Understanding the tumor microenvironment (TME) is essential for the development of effective treatments for cancer patients. Traditional multi...
The 2020 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to rage. While PCR-based assays are used for viral diagnosis, high through-put, rapid s...
Background: CDK4/6 inhibitors increase tumor immunogenicity in preclinical models of breast cancer and several trials combining CDK4/6 inhibitors and anti-PD1/PDL1 therapies are underway. Ho...
Whether you are performing killing assays, characterizing the tumor microenvironment, or investigating immunogenicity, primary cells are essential for the discovery of new therapeutics. Conc...
DATE: December 11, 2019 TIME: 7:00am PST, 10:00am EST Rapid growth in the cell and gene therapy industry has generated an urgent need for robust analytics around characterization of both vec...
DATE: December 5, 2019TIME: 9:00am PST, 12:00pm EST Characterization of the spatial distribution and abundance of proteins and mRNAs with morphological context within tissues e...
Tumor mutational burden (TMB) is an emerging biomarker that correlates with response to immunotherapeutic agents, such as checkpoint inhibitors. Recent studies indicate that a high mutation l...
DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
Whether you are performing killing assays, immunophenotyping of TILs, characterizing the tumor microenvironment, or investigating immunogenicity, primary cells are essential for the discovery...
As the pace of biotherapeutic approvals increases, so does the pressure on makers of new biologics to complete their development processes faster and more efficiently. The success of the drug...
DATE: January 25, 2018TIME: 10:00am PST, 1:00pm EST, 6:00pm GMTOncolytic virotherapy, the use of viral vectors to treat cancer, holds huge promise. Viruses are natural DNA delivery vehi...
There has been a great deal of renewed attention in immuno-oncology over the last decade. Therapies for cancer are being developed, approved, and administered that can either initiate,...
DATE: August 31, 2017TIME: 7:00am PT, 10:00am ET, 4:00pm CETA tuberculosis (TB) vaccine consisting of a recombinant fusion protein (referred to as H4) combined with a novel sy...
Follow
